ECG Core Lab

Richmond Pharmacology’s Core ECG Laboratory was established in 2004 to provide centralized digital and manual ECG data analysis for Richmond Pharmacology’s in house TQT trials, in addition to ECG reading, analysis and reporting for clinical trials conducted at other centres.

As a standard Richmond Pharmacology use FDA compliant Digital 12-Lead ECG and Digital 12-Lead Holter devices for collection, transmission and processing of digital ECG and Holter recordings for TQT studies.

Each bedside has a GE MAC 1200, 12-lead ECG machine connected to the MUSE® Server allowing for storage of thousands of digital ECG’s. These digitized ECG's are available to our cardiological sciences team as required for subsequent digitized reading, analysis and reporting. The system is FDA 21 CFR Part 11 compliant with secure authorized user access and password protection to allow access to users for their required access levels only. A detailed audit trail is available and includes the username, date and time of access of any individual using the system and what addition or change they made to the database.

Prior to commencement of a study involving Richmond Pharmacology, all digital 12-Lead ECG machines used for the project are configured to ensure that every ECG data file contains the exact and correct information in FDA compliant format (HL7) as per ICH E14. The configuration of each of Richmond Pharmacology’s ECG machines used in our in house or external TQT study undergoes a vigorous validation process, including acquisition and transfer of test ECGs from the machine’s simulator. To further standardise the process, the same machine is always used for the same subject throughout the study. The standard configuration and validation process is fully documented and available to clients upon request.

The digital 12-Lead Holter devices used by Richmond Pharmacology are designed to be used for FDA compliant arrhythmia analysis. The data obtained from these digitised 12-Lead Holter devices ensure Richmond Pharmacology’s core lab can report on ventricular and supraventricular arrhythmias, and ischemia parameters in addition to quantifying heart rates and providing qualitative reporting of cardiac rhythm information.

Our experts

Professor Camm - Professor of Cardiology

Professor Camm's major speciality is cardiac arrhythmias but he is also much involved in clinical cardiac electrophysiology, cardiac pacemakers and risk stratification in post myocardial infarction, heart failure and cardiomyopathy drugs.

Read biography

Dr Jorg Taubel - MD FFPM
(CEO)

Dr Jorg Taubel is a medical practitioner and CEO of Richmond Pharmacology which he co-founded in 2001. He has worked in clinical pharmacology for over 24 years and during that time he has conducted more than 400 early phase studies..

Read biography

Experience

  • Track record of 100% success in conducting QTC studies
  • Many of our QTc studies have been published.

Set-up

  • State of the art methods and equipment
  • Tried and tested processing for ECG adjudication and data analysis

We are

  • Excellence in ECG acquisition allows meaningful ECG analysis
  • Option to include a non-pharmacological method of proving assay sensitivity

Latest news

Upcoming Event

The 41st Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

4 – 5 December 2020
The 41st Annual Scientific meeting focuses on international collaboration in the pursuit of drug discovery and drug development.
View event

Marking a milestone for gene editing

November 10, 2020
We are pleased to share that Richmond Pharmacology, in partnership with Intellia Therapeutics and the Royal Free Hospital, have treated the first patient in a landmark CRISPR/Cas9 clinical trial of NTLA-2001
Read more

Richmond Pharmacology is delighted to confirm partnership with Intellia Therapeutics

October 20, 2020
Phase I study of Intellia Therapeutic’s NTLA-2001 for the treatment of hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN)
Read more

Richmond Pharmacology supports ReViral with the development of Sisunatovir

September 9, 2020
ReViral has confirmed the FDA has granted Fast Track designation to Sisunatovir.
Read more